Irinotecan Hydrochloride Hydrate Intravenous Infusion 100mg/5mL (Irinotecan HCl Infusion “NK” / イリノテカン塩酸塩点滴静注液100mg「NK」)

JPY ¥3,600

Japanese Antineoplastic Agent (Irinotecan Hydrochloride Hydrate 100mg/5mL). For IV infusion in multiple malignancies including lung, colorectal, gastric, and pancreatic cancers. 5mL x 1 vial. Mfd. by Viatris Healthcare LLC, Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥3,312
10 - 19 12% JPY ¥3,168
20 + 18% JPY ¥2,952
SKU: IRI-100-INJ Category:

Description

Product Overview / 商品概要

Irinotecan Hydrochloride Hydrate Intravenous Infusion 100mg/5mL “NK” (イリノテカン塩酸塩点滴静注液100mg「NK」)
Generic: Irinotecan Hydrochloride Hydrate / イリノテカン塩酸塩水和物
Therapeutic Category: Antineoplastic Agent / 抗悪性腫瘍剤
Manufactured by: Viatris Healthcare LLC / ヴィアトリス・ヘルスケア合同会社

Composition & Specification / 組成・規格

Active Ingredient: Irinotecan Hydrochloride Hydrate 100.0mg per vial / 1バイアル中 イリノテカン塩酸塩水和物 100.0mg
Additives: D-Sorbitol 225.0mg, Lactic acid 4.5mg, pH adjuster q.s. / D-ソルビトール 225.0mg、乳酸 4.5mg、pH調節剤 適量
Appearance: Pale yellow clear solution, pH 3.0–4.0, Osmotic pressure ratio 1.0–1.3 (relative to physiological saline)
外観: 微黄色澄明の液、pH 3.0〜4.0、浸透圧比 1.0〜1.3(生理食塩液に対する比)

Indications / 効能効果

EN: Small cell lung cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, gastric cancer (inoperable or relapsed), colorectal cancer (inoperable or relapsed), breast cancer (inoperable or relapsed), squamous cell carcinoma, malignant lymphoma (non-Hodgkin’s lymphoma), pediatric malignant solid tumors, unresectable pancreatic cancer
JA: 小細胞肺癌、非小細胞肺癌、子宮頸癌、卵巣癌、胃癌(手術不能又は再発)、結腸・直腸癌(手術不能又は再発)、乳癌(手術不能又は再発)、有棘細胞癌、悪性リンパ腫(非ホジキンリンパ腫)、小児悪性固形腫瘍、治癒切除不能な膵癌

Dosage and Administration / 用法用量

EN: Regimen A: Usually 100mg/m2 IV infusion once daily at 1-week intervals for 3–4 doses, followed by at least 2 weeks rest; repeat as one cycle. Regimen B: Usually 150mg/m2 IV infusion once daily at 2-week intervals for 2–3 doses, followed by at least 3 weeks rest; repeat as one cycle. Regimen C: Usually 40mg/m2 IV infusion once daily for 3 consecutive days, repeated weekly 2–3 times, followed by at least 2 weeks rest. Regimen D: Usually 20mg/m2 IV infusion once daily for 5 consecutive days, repeated weekly twice, followed by at least 1 week rest. Regimen E: Usually 180mg/m2 IV infusion once daily, followed by at least 2 weeks rest; repeat as one cycle. Regimens A, B, E: dilute in ≥500mL infusion fluid, administer over ≥90 minutes. Regimen C: dilute in ≥250mL, administer over ≥60 minutes. Regimen D: dilute in ≥100mL, administer over ≥60 minutes.
JA: A法:通常、成人に1日1回、100mg/m2を1週間間隔で3〜4回点滴静注し、少なくとも2週間休薬する。これを1クールとして繰り返す。B法:通常、成人に1日1回、150mg/m2を2週間間隔で2〜3回点滴静注し、少なくとも3週間休薬する。これを1クールとして繰り返す。C法:通常、成人に1日1回、40mg/m2を3日間連日点滴静注する。1週毎に2〜3回繰り返し、少なくとも2週間休薬する。D法:通常、1日1回、20mg/m2を5日間連日点滴静注する。1週毎に2回繰り返し、少なくとも1週間休薬する。E法:通常、成人に1日1回、180mg/m2を点滴静注し、少なくとも2週間休薬する。A法・B法・E法は500mL以上の輸液に混和し90分以上、C法は250mL以上に混和し60分以上、D法は100mL以上に混和し60分以上かけて点滴静注する。

Contraindications / 禁忌

EN: Patients with bone marrow suppression; patients with concurrent infections; patients with diarrhea (watery stools); patients with paralytic ileus or intestinal obstruction; patients with interstitial pneumonia or pulmonary fibrosis; patients with large amounts of ascites or pleural effusion; patients with jaundice; patients receiving atazanavir sulfate; patients with a history of hypersensitivity to any component of this product
JA: 骨髄機能抑制のある患者、感染症を合併している患者、下痢(水様便)のある患者、腸管麻痺・腸閉塞のある患者、間質性肺炎又は肺線維症の患者、多量の腹水・胸水のある患者、黄疸のある患者、アタザナビル硫酸塩を投与中の患者、本剤の成分に対し過敏症の既往歴のある患者

Regulatory Information / 規制情報

Approval No.: 22100AMX00327
Sales Started: May 2009 / 2009年5月
Classification Code: 87424
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年

Packaging / 包装

Main Package (for sale): 5mL x 1 vial / 5mL[1バイアル]
Other Available Packages (by special order): 5mL [1 vial]

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Irinotecan Hydrochloride Hydrate Intravenous Infusion 100mg/5mL (Irinotecan HCl Infusion “NK” / イリノテカン塩酸塩点滴静注液100mg「NK」)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Irinotecan Hydrochloride Hydrate Intravenous Infusion 100mg

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.